Gonzalez-Murillo Africa, Lozano M Luz, Montini Eugenio, Bueren Juan A, Guenechea Guillermo
Hematopoiesis and Gene Therapy Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Eufermedades Raras (CIBERER), Madrid, Spain.
Blood. 2008 Oct 15;112(8):3138-47. doi: 10.1182/blood-2008-03-142661. Epub 2008 Aug 6.
Recent studies of retroviral-mediated gene transfer have shown that retroviral integrations themselves may trigger nonmalignant clonal expansion of hematopoietic stem cells (HSCs) in transplant recipients. These observations suggested that previous conclusions of HSC dynamics based on gamma-retroviral gene marking should be confirmed with improved vectors having a more limited capacity to transactivate endogenous genes. Because of the low trans-activation activity of self-inactivating lentiviral vectors (LVs), we have investigated whether the LV marking of mouse HSCs induces a competitive repopulation advantage in recipients of serially transplants. As deduced from analyses conducted in primary and secondary recipients, we concluded that lentivirally transduced HSCs have no competitive repopulation advantages over untransduced HSCs. By linear amplification-mediated polymerase chain reaction (LAM-PCR) analysis, we characterized LV-targeted genes in HSC clones that engrafted up to quaternary recipients. Although 9 clones harbored integrations close to defined retroviral insertion sites, none was characterized as a common integration site, and none was present in HSC clones repopulating quaternary recipients. Taken together, our results show unaltered repopulation properties of HSCs transduced with LVs, and confirm early studies suggesting the natural capacity of a few HSC clones to generate a monoclonal or oligoclonal hematopoiesis in transplant recipients.
近期关于逆转录病毒介导的基因转移的研究表明,逆转录病毒整合本身可能会触发移植受者体内造血干细胞(HSC)的非恶性克隆性扩增。这些观察结果表明,之前基于γ-逆转录病毒基因标记得出的HSC动力学结论,应该用激活内源性基因能力更有限的改良载体来加以证实。由于自失活慢病毒载体(LV)的低反式激活活性,我们研究了小鼠HSC的LV标记是否会在连续移植的受者中诱导竞争性再增殖优势。从对初级和次级受者进行的分析推断,我们得出结论,经慢病毒转导的HSC与未转导的HSC相比没有竞争性再增殖优势。通过线性扩增介导的聚合酶链反应(LAM-PCR)分析,我们对植入至四级受者的HSC克隆中的LV靶向基因进行了表征。尽管9个克隆含有靠近确定的逆转录病毒插入位点的整合,但没有一个被表征为常见整合位点,并且在再增殖至四级受者的HSC克隆中均未出现。综上所述,我们的结果表明经LV转导的HSC的再增殖特性未改变,并证实了早期研究,即少数HSC克隆在移植受者中具有产生单克隆或寡克隆造血的天然能力。